Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2024 Jan 12;16(2):249.
doi: 10.3390/nu16020249.

Effectiveness of a Food Supplement Based on Glucomannan, D-Chiro-Inositol, Cinnamomum zeylanicum Blume and Inulin in Patients with Metabolic Syndrome

Roberto Citarrella  1 , Roberta Chianetta  1 , Simona Amodeo  1 , Luigi Mirarchi  2 , Anna Licata  1 , Maurizio Soresi  1 , Nicola Veronese  1 , Mario Barbagallo  1 , Lydia Giannitrapani  1   3
Affiliations
Randomized Controlled Trial

Effectiveness of a Food Supplement Based on Glucomannan, D-Chiro-Inositol, Cinnamomum zeylanicum Blume and Inulin in Patients with Metabolic Syndrome

Roberto Citarrella et al. Nutrients. .

Abstract

Metabolic syndrome (MetS) is associated with cardiovascular risk factors, such as insulin resistance, dyslipidaemia, hypertension and abdominal obesity. Given the growing need to investigate food supplements with positive health effects, this study was aimed at testing the benefits of a specific supplement for people with MetS. Fifty-eight subjects with MetS and T2DM or impaired glucose tolerance assuming metformin, were randomly assigned to take a food supplement of glucomannan, D-chiro-inositol, Cinnamomum zeylanicum blume and inulin at a daily fixed dose of 4 g orally for four months. Body weight, waist circumference, plasma lipid profile (total cholesterol, LDL, HDL and triglyc-erides), plasma glycaemic profile and visceral adiposity index (VAI) were measured at baseline and after four months of supplementation. After 16 weeks, in subjects with T2DM or insulin resistance who took the supplement (+ metformin), there was a significant reduction in body weight and BMI (p < 0.0001), serum insulin (p < 0.05) and the HOMA index (p < 0.01), as well as in the lipaemic pattern, with a significant improvement in total serum cholesterol (p < 0.005), triglycerides (p < 0.03) and LDL (p < 0.02). Our study shows that the food supplement tested is a valid and safe alternative therapeutic approach in the management of MetS and all its resulting risk factors, as its efficacy has been demonstrated across anthropometric, glucose, lipid and hepatic parameters.

Keywords: Cinnamomum zeylanicum blume; D-chiro-inositol; T2DM; glucomannan; inulin; metabolic syndrome.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Variations in the main anthropometric parameters in the treated and in the control group [weight (−3.66 vs. −0.36 kg), body mass index (−5.80 vs. −0.49 kg/m2), waist circumference (−1.85 vs. 0 cm) and VAI (−6.07 vs. −7.55)].
Figure 2
Figure 2
Variations in the main glucometabolic parameters in the treated and in the control group [(HbA1c (−4.18 vs. −2.62%), fasting plasma glucose (−7.21 vs. −5.00 mg/dL), serum insulin (−8.95 vs. −9.17 mIU/L) and HOMA index (−18.69 vs. −16.98)].
Figure 3
Figure 3
Variations in lipid profile, kidney and liver function tests in the case study.
See this image and copyright information in PMC

References

    1. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106:3143–3421. doi: 10.1161/circ.106.25.3143. - DOI - PubMed
    1. Blüher M. Obesity: Global epidemiology and pathogenesis. Nat. Rev. Endocrinol. 2019;15:288–298. doi: 10.1038/s41574-019-0176-8. - DOI - PubMed
    1. De la Iglesia R., Loria-Kohen V., Zulet M.A., Martinez J.A., Reglero G., Ramirez de Molina A. Dietary strategies implicated in the prevention and treatment of metabolic syndrome. Int. J. Mol. Sci. 2016;17:1877. doi: 10.3390/ijms17111877. - DOI - PMC - PubMed
    1. Boulé N.G., Haddad E., Kenny G.P., Wells G.A., Sigal R.J. Effects of exercise on glycemic control and body mass in type 2 diabetes mellitus: A meta-analysis of controlled clinical trials. J. Am. Med. Assoc. 2001;286:1218–1227. doi: 10.1001/jama.286.10.1218. - DOI - PubMed
    1. Bellentani S., Grave R.D., Suppini A., Marchesini G., Flin F.L.I.N. Behavior therapy for nonalcoholic fatty liver disease: The need for a multidisciplinary approach. Hepatology. 2008;47:746–754. doi: 10.1002/hep.22009. - DOI - PubMed

Publication types